Leukapheresis Device Market Report 2026

Leukapheresis Device Market Overview

• Leukapheresis Device market size has reached to $0.7 billion in 2025 • Expected to grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.4% • Growth Driver: Rising Blood Disorders Fuel Growth In The Market Due To Aging Population And Increasing Disease Burden • Market Trend: Localization Investments Boosting Leukapheresis Device Availability In China • North America was the largest region in 2025.

What Is Covered Under Leukapheresis Device Market?

A leukapheresis device is a medical instrument used to selectively separate and collect white blood cells (leukocytes) from a patient’s or donor’s blood using centrifugation or filtration techniques. It plays a critical role in treatments, leukemia management, stem cell transplantation, and autoimmune disease therapy, and is also used in clinical research and diagnostic applications. The main device types of leukapheresis devices are therapeutic leukapheresis, cytapheresis, stem cell collection, research applications, leukapheresis columns and cell separators, leukapheresis disposables, and apheresis devices. Therapeutic leukapheresis is a clinical procedure used to remove excess or abnormal white blood cells from a patient's bloodstream to relieve symptoms or prevent related complications. It consists of various components such as leukapheresis machines, blood collection sets, medical consumables, and filtration units. The varied end users encompass hospitals, academic and research institutions, pharmaceutical and biotechnology companies, blood centers, and blood component providers.

What Is The Leukapheresis Device Market Growth Forecast?

The leukapheresis device market size is expected to see strong growth in the next few years. It will grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to demand for portable leukapheresis systems, integration of ai and automation in devices, expansion of biopharmaceutical research, regulatory approvals for advanced apheresis devices, rising investments in precision medicine. Major trends in the forecast period include personalized leukapheresis treatments, minimally invasive apheresis techniques, portable and point-of-care leukapheresis devices, integration of real-time monitoring systems, enhanced automation and workflow efficiency.

What Is The Driver Of The Leukapheresis Device Market?

The rising prevalence of blood-related disorders is expected to propel the growth of the leukapheresis device market going forward. Blood-related disorders are conditions that impact the structure or function of blood cells, resulting in problems with oxygen delivery, immune response, or blood clotting. The increasing incidence of blood-related disorders is primarily attributed to an aging population, as older individuals are more susceptible to conditions such as anemia, leukemia, and various hematological disorders. Leukapheresis devices assist in the management of these disorders by selectively extracting excess or abnormal white blood cells from the bloodstream, thereby helping to alleviate symptoms and reduce complications in diseases such as leukemia and autoimmune conditions. For instance, in March 2024, according to the Leukaemia Foundation, an Australia-based non-profit organization, around 19,500 Australians were diagnosed with blood cancer, including leukemia, lymphoma, and myeloma, with nearly 43% facing significant out-of-pocket treatment costs and 42% taking over three months off work highlighting both the rising incidence and the financial burden on patients and their families compared to previous years. Therefore, the rising prevalence of blood-related disorders is driving the growth of the leukapheresis device industry.

Key Players In The Global Leukapheresis Device Market

Major companies operating in the leukapheresis device market are Fresenius SE and Co. KGaA, Asahi Kasei Medical Co. Ltd, Baxter International Inc., Grifols S.A., TERUMO BCT INC., Kaneka Corporation, Nikkiso Co. Ltd, Haemonetics Corporation, Miltenyi Biotec GmbH, Macopharma, B. Braun Melsungen AG, Kawasumi Laboratories Inc., Beijing Zksk Technology Co. Ltd, Puriblood Medical Co. Ltd, Fresenius Kabi AG, JMS Co. Ltd, HemaCare Corporation, Medica Group PLC, LivaNova PLC, Cytiva, BioSafe Group SA, Terumo Corporation

Global Leukapheresis Device Market Trends and Insights

Major companies operating in the leukapheresis device market are focusing on investing in regional manufacturing capabilities to enhance local access to high-quality therapeutic devices and support national healthcare goals. Regional manufacturing investments help create efficient and flexible supply chains that ensure timely delivery, reduced dependency on imports, and improved affordability of advanced blood and cell collection systems. For instance, in November 2024, Terumo Blood and Cell Technologies, a US-based medical technology company, partnered with Terumo Medical Products (Hangzhou) Co., Ltd., a China-based medical technology subsidiary company, to launch localized production in Hangzhou, China. This strategic move involves the local manufacturing of key leukapheresis products, including the Trima Accel Automated Blood Collection System and the Spectra Optia Apheresis System, both of which are widely adopted in China for therapeutic apheresis, stem cell collection, and blood component separation.

What Are Latest Mergers And Acquisitions In The Leukapheresis Device Market?

In November 2025, Terumo Blood and Cell Technologies (Terumo BCT), a US-based medical technology company, partnered with Santersus AG to advance a novel therapeutic apheresis technology aimed at improving clinical outcomes for patients with sepsis. With this partnership, Terumo BCT and Santersus aim to combine Santersus’ NucleoCapture blood purification device with Terumo BCT’s Spectra Optia™ Apheresis System to selectively remove neutrophil extracellular traps (NETs) from blood, potentially reducing sepsis mortality and enhancing patient care. Santersus AG is a Switzerland-based therapeutic apheresis company specializing in medical devices for blood purification in critical illnesses.

What Defines the Leukapheresis Device Market?

The leukapheresis device market consists of sales of leukapheresis software and monitoring systems, blood flow controllers and pumps, and centrifuge rotors and tubing sets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Leukapheresis Device Market Report 2026?

The leukapheresis device market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leukapheresis device industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.